IDEAYA Biosciences, Inc. (IDYA)
Data as of , from SEC Form 4 filings.
See up to 3 months of IDYA. The 7-day demo opens the 1M and 3M ranges and puts IDYA on your watchlist.
Start 7-day demoLatest IDYA insider trades
About IDEAYA Biosciences, Inc. (IDYA)
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
- SOUTH SAN FRANCISCO, CA
- 145
- 2019
- XNAS
IDYA Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 2 | 26,338 | $985K |
| Option exercise | 2 | 52,676 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
IDYA insider transactions (Form 4)
2718 Form 4 filings on record, the earliest from Jun 24, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Yujiro S. Hata - Officer | Option exercise | Common Stock | 26,338 | $4.31 | $114K | |
| Yujiro S. Hata - Officer | Open-market sale | Common Stock | 25,538 | $37.39 footnote F2 | $955K | |
| Yujiro S. Hata - Officer | Open-market sale | Common Stock | 800 | $38.26 footnote F3 | $31K | |
| Yujiro S. Hata - Officer | Option exercise | Stock Option (right to buy) | 26,338 | $0.00 | - | |
| ||||||
| Briseno Andres Ruiz - Officer | Option exercise | Common Stock | 9,550 | $12.86 | $123K | |
| Briseno Andres Ruiz - Officer | Open-market sale | Common Stock | 9,550 | $40.01 footnote F2 | $382K | |
| Briseno Andres Ruiz - Officer | Option exercise | Stock Option (Right to Buy) | 9,550 | $0.00 | - | |
| ||||||
| Wendy L. Yarno | Grant or award | Stock Option (right to buy) | 20,000 | $0.00 | - | |
| Jeffrey Stein | Grant or award | Stock Option (right to buy) | 20,000 | $0.00 | - | |
| Terry J. Rosen | Grant or award | Stock Option (right to buy) | 20,000 | $0.00 | - | |
| Scott W. Morrison | Grant or award | Stock Option (right to buy) | 20,000 | $0.00 | - | |
| Catherine J. Mackey | Grant or award | Stock Option (right to buy) | 20,000 | $0.00 | - | |
| Malcolm Garret Hampton | Grant or award | Stock Option (right to buy) | 20,000 | $0.00 | - | |
| Jeffrey Stein | Open-market purchase | Common Stock | 50,000 | $32.96 footnote F1 | $1.65M | |
| ||||||
| Joshua Bleharski - Officer | Grant or award | Stock Option (right to buy) | 170,000 | $0.00 | - | |
| Michael Anthony White - Officer | Grant or award | Stock Option (right to buy) | 190,000 | $0.00 | - | |
| Darrin Beaupre - Officer | Grant or award | Stock Option (right to buy) | 175,000 | $0.00 | - | |
| Stuart Dorman - Officer | Grant or award | Stock Option (right to buy) | 155,000 | $0.00 | - | |
| Yujiro S. Hata - Officer | Grant or award | Stock Option (right to buy) | 600,000 | $0.00 | - | |
| Douglas B. Snyder - Officer | Grant or award | Common Stock | 1,039 | $16.91 | $18K | |
| Douglas B. Snyder - Officer | Grant or award | Common Stock | 1,041 | $16.91 | $18K | |
| Douglas B. Snyder - Officer | Grant or award | Stock Option (right to buy) | 130,000 | $0.00 | - | |
| Briseno Andres Ruiz - Officer | Grant or award | Common Stock | 682 | $23.26 | $16K | |
| Briseno Andres Ruiz - Officer | Grant or award | Common Stock | 1,253 | $16.91 | $21K | |
| Briseno Andres Ruiz - Officer | Grant or award | Stock Option (right to buy) | 80,000 | $0.00 | - | |
| Terry J. Rosen | Grant or award | Stock Option (right to buy) | 20,000 | $0.00 | - | |
| Wendy L. Yarno | Grant or award | Stock Option (right to buy) | 20,000 | $0.00 | - | |
Recent IDYA Form 144 notices of proposed sale
2An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| YUJIRO HATA | CEO | 230,316 | $8.80M | View on EDGAR | |
| - | - | - | - |
IDYA insider trading FAQ
What is the latest insider trade for IDYA?
IDEAYA Biosciences, Inc. (IDYA) had 1 insider filing in the last 90 days, with the most recent on 2026-10-08. The full record for IDYA runs to 18 Form 4 filings, the earliest from 2025-06-24. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying IDYA stock?
No insider purchases of IDYA were filed in the last 90 days. 1 purchase is on record for this company.
How many insiders are selling IDYA stock?
2 insider sales of IDYA were filed in the last 90 days, totaling $985K.
Where can I see IDYA SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects IDYA Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Yujiro S. Hata view on EDGAR
- - Briseno Andres Ruiz view on EDGAR
- - Wendy L. Yarno view on EDGAR
- - Jeffrey Stein view on EDGAR
- - Terry J. Rosen view on EDGAR
- - Scott W. Morrison view on EDGAR
- - Catherine J. Mackey view on EDGAR
- - Malcolm Garret Hampton view on EDGAR
- - Jeffrey Stein view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where IDYA's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow IDYA with a 7-day demo
- IDYA on your watchlist
- Every IDYA Form 4 filing on record
- Up to 3 months of IDYA price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
